Literature DB >> 11827693

Elevated hexokinase increases cardiac glycolysis in transgenic mice.

Qiangrong Liang1, Rajakumar V Donthi, Patricia M Kralik, Paul N Epstein.   

Abstract

OBJECTIVE: Cardiac glucose metabolism is critical to normal and pathological function. The significance of the first committed metabolic step, glucose phosphorylation, has not been established. In this study a new transgenic model was developed in order to investigate the importance of this enzymatic step in cardiac glycolysis.
METHODS: Transgenic mice were produced that overexpress yeast hexokinase B under the control of a cardiac specific promoter. Yeast hexokinase B is a high affinity enzyme that is not inhibited by glucose-6-phosphate. Hexokinase enzyme activity was measured by a modified radiometric procedure. Cardiac glucose metabolism and contractility were measured in the Langendorff mode. Cardiac glycogen content and glucose-6-phosphate independent glycogen synthase activity were also determined.
RESULTS: In transgenic hearts hexokinase activity was significantly elevated and increased glucose metabolism, particularly in the presence of insulin and during cardiac reperfusion. However during ischemic perfusion the effect of the transgene on glycolysis was minimal. Under all conditions tested there was no effect of hexokinase on contractility. Glycogen content of transgenic hearts was elevated 2-fold and glucose-6-phosphate independent glycogen synthase was also increased.
CONCLUSION: These results demonstrate that glucose phosphorylation is a key step in determining cardiac glucose metabolism under oxidative conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827693     DOI: 10.1016/s0008-6363(01)00495-3

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

Review 1.  Hexokinases and cardioprotection.

Authors:  Guillaume Calmettes; Bernard Ribalet; Scott John; Paavo Korge; Peipei Ping; James N Weiss
Journal:  J Mol Cell Cardiol       Date:  2014-09-26       Impact factor: 5.000

Review 2.  Metabolism in cardiomyopathy: every substrate matters.

Authors:  Julia Ritterhoff; Rong Tian
Journal:  Cardiovasc Res       Date:  2017-03-15       Impact factor: 10.787

3.  Fucoxanthin Attenuates the Reprogramming of Energy Metabolism during the Activation of Hepatic Stellate Cells.

Authors:  Minkyung Bae; Mi-Bo Kim; Ji-Young Lee
Journal:  Nutrients       Date:  2022-05-01       Impact factor: 6.706

4.  Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia.

Authors:  Qianwen Wang; Rajakumar V Donthi; Jianxun Wang; Alex J Lange; Lewis J Watson; Steven P Jones; Paul N Epstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

Review 5.  Mitochondrial hexokinase and cardioprotection of the intact heart.

Authors:  C J Zuurbier; K M A Smeele; O Eerbeek
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

6.  Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction.

Authors:  Jianxun Wang; Jianxiang Xu; Qianwen Wang; Robert E Brainard; Lewis J Watson; Steven P Jones; Paul N Epstein
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

7.  Epinephrine responsiveness is reduced in livers from trained mice.

Authors:  Hana A Dibe; Logan K Townsend; Greg L McKie; David C Wright
Journal:  Physiol Rep       Date:  2020-02

8.  Forced expression of miR-143 and -145 in cardiomyocytes induces cardiomyopathy with a reductive redox shift.

Authors:  Jun Ueda; Takehiro Ogata; Kota Ogawa; Akiko Noda; Rumiko Matsuyama; Yuji Nishizawa; Shanlou Qiao; Satoru Iwata; Morihiro Ito; Yoshitaka Fujihara; Masatoshi Ichihara; Koichi Adachi; Yuji Takaoka; Takashi Iwamoto
Journal:  Cell Mol Biol Lett       Date:  2020-08-24       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.